Azeliragon - vTv Therapeutics

Drug Profile

Azeliragon - vTv Therapeutics

Alternative Names: PF-04494700; PF-4494700; TTP-488

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransTech Pharma
  • Developer Pfizer; TransTech Pharma; vTv Therapeutics LLC
  • Class Antidementias; Diethylamines; Imidazoles; Small molecules
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists; Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 04 Aug 2017 vTv Therapeutics has patent protection for azeliragon in USA
  • 16 Jul 2017 Pharmacokinetics and safety data of azeliragon in healthy subjects presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 16 Jul 2017 Pharmacokinetics data from pooled analysis in Healthy volunteers study, Alzheimer’s disease, Type 2 diabetes and persistent albuminuria studies presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top